-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
Bristol-Myers Squibb Company Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Revenue |
|
$42.52B | $46.39B | $46.16B | $45.01B |
| Cost of Revenue |
|
$11.77B | $9.94B | $10.14B | $10.69B |
| Gross Profit |
|
$30.75B | $36.45B | $36.02B | $34.31B |
| Research & Development |
|
$11.14B | $10.20B | $9.51B | $9.30B |
| Selling,General & Administrative |
|
$7.66B | $7.69B | $7.81B | $7.77B |
| Operating Expense |
|
$28.57B | $27.91B | $26.92B | $17.89B |
| Operating Income |
|
$5.13B | $10.16B | $10.33B | $17.24B |
| Net Income |
|
-$9.00B | $6.99B | $6.33B | $8.03B |
Bristol-Myers Squibb Company Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$14.55B | $13.98B | $9.12B | $12.28B |
| Inventories |
|
$2.07B | $2.10B | $2.34B | $2.66B |
| Total Current Assets |
|
$30.19B | $33.26B | $27.27B | $31.77B |
| Property,Plant and Equipment |
|
$6.75B | $6.97B | $7.48B | $8.04B |
| Goodwill |
|
$20.55B | $20.50B | $21.15B | $21.17B |
| Total Assets |
|
$118.48B | $109.31B | $96.82B | $95.16B |
| Total Liabilities |
|
$80.60B | $73.31B | $65.70B | $65.67B |
| Retained Earnings |
|
$21.28B | $23.82B | $25.50B | $28.77B |
| Total Shareholder Equity |
|
$37.82B | $35.95B | $31.06B | $29.43B |
| Common Stock |
|
$292.00M | $292.00M | $292.00M | $292.00M |
Bristol-Myers Squibb Company Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$10.38B | $10.69B | $10.28B | $9.76B |
| Dividends Payout |
|
-$4.08B | -$4.40B | -$4.63B | -$4.74B |
| Capital Expenditures (Capex) |
|
-$753.00M | -$973.00M | -$1.12B | -$1.21B |
| Free Cash Flow (FCF) |
|
$13.30B | $15.23B | $11.95B | $12.65B |
Bristol-Myers Squibb Company Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Gross Profit |
|
$30.75B | $36.45B | $36.02B | $34.31B |
| Gross Profit Margin (%) |
|
72.31% | 78.57% | 78.04% | 76.24% |
| Operating Income |
|
$5.13B | $10.16B | $10.33B | $17.24B |
| Operating Income Margin (%) |
|
12.06% | 21.90% | 22.37% | 38.31% |
| Net Income |
|
-$9.00B | $6.99B | $6.33B | $8.03B |
| Net Income Margin (%) |
|
-21.16% | 15.08% | 13.71% | 17.83% |
| EBITDA |
|
$5.04B | $20.19B | $19.23B | $19.42B |
| EBITDA Margin (%) |
|
34.85% | 43.51% | 43.16% | 43.14% |
Bristol-Myers Squibb Company Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
-23.78% | 19.46% | 20.37% | 27.27% |
| Return on Assets (ROA) |
|
-7.59% | 6.40% | 6.53% | 8.43% |
| Debt to Equity |
|
133.99% | 123.94% | 126.59% | 135.14% |
| Debt to total asset |
|
42.77% | 40.76% | 40.61% | 41.80% |
| Enterprise value to revenue |
|
4.17 | 3.67 | 4.00 | 3.03 |
| Enterprise value to EBITDA |
|
35.19 | 8.42 | 9.61 | 7.01 |
| Enterprise value |
|
$177.19B | $170.10B | $184.85B | $136.16B |
| Cash to Debt |
|
27.73% | 36.38% | 33.23% | 34.85% |
| Tax Rate (%) |
|
-30.91% | 13.39% | 17.74% | 4.74% |
| Payout Ratio |
|
-45.30% | 62.85% | 73.24% | 59.12% |
